TIOTROPIUM BROMIDE MARKET

INTRODUCTION

Tiotropium bromide is a long-acting bronchodilator LAMA: long acting muscarinic antagonist used in the treatment of chronic obstructive pulmonary disease and asthma. It is utilized through mouth inhalation. In most cases, onset starts within a half-hour and lasts for 24 hours.

Angioedema, increasing bronchospasm, and QT prolongation are examples of severe adverse effects. Since such use has not been thoroughly researched, preliminary evidence does not indicate risk during pregnancy. It is an anticholinergic drug that prevents smooth muscle from being affected by acetylcholine.

Tiotropium is used to treat chronic obstructive pulmonary disease on an ongoing basis. Those with moderate to severe asthma who are taking medium to high doses of inhaled corticosteroids may also use it as an adjunctive therapy.

However, it is not recommended for sudden worsening of asthma or sudden exacerbations of COPD Olodaterol, a long-acting beta-agonist, and tiotropium are other combined inhalers used to treat COPD.

Tiotropium, sometimes known as antimuscarinic or anticholinergic medication, is a muscarinic receptor antagonist. When applied topically, it mostly affects M3 muscarinic receptors found on smooth muscle cells and submucosal glands, despite the fact that it does not exhibit selectivity for certain muscarinic receptors.

This results in a decrease in mucus output and smooth muscle contraction, which has the bronchodilator effect. Its antimuscarinic properties are primarily responsible for any negative effects.

Dry mouth and/or throat discomfort are typical adverse medication effects. Urinary retention, constipation, acute angle closure glaucoma, palpitations, particularly supraventricular tachycardia and atrial fibrillation, allergies, and other conditions are uncommonly treated.

TIOTROPIUM BROMIDE MARKET SIZE AND FORECAST

The Global Tiotropium bromide Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

TIOTROPIUM BROMIDE MARKET NEW PRODUCT LAUNCH

Under the trade name Tio give, Glenmark has launched the tiotropium bromide dry powder inhaler. Chronic lung inflammation, lung tissue destruction, and airway narrowing are all symptoms of COPD, which makes breathing challenging. There are numerous variations of the disorder, but little is known about what causes these variations and how to treat the various disease forms.

TIOTROPIUM BROMIDE MARKET COMPANY PROFILE

• Glenmark
• Maya Biotech Pvt. Ltd
• LUDOTROP. 
• Tiodom 18 
• Lupin Laboratories Ltd.
• Manus Aktteva Biopharma LLP
• Enomark Healthcare Pvt Ltd.

THIS TIOTROPIUM BROMIDE MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many Tiotropium bromide are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global Tiotropium bromide and key vendor selection criteria
3. Where is the Tiotropium bromide manufactured? What is the average margin per unit?
4. Market share of Global Tiotropium bromide market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global Tiotropium bromide in-house
6. key predictions for next 5 years in Global Tiotropium bromide market
7. Average B-2-B Tiotropium bromide market price in all segments
8. Latest trends in Tiotropium bromide market, by every market segment
9. The market size (both volume and value) of the Tiotropium bromide market in 2024-2030 and every year in between?
10. Production breakup of Tiotropium bromide market, by suppliers and their OEM relationship